LCM
OVID icon

Laurion Capital Management’s Ovid Therapeutics OVID Stock Holding History

Laurion Capital Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-90,236
Closed -$374K – 998
2019
Q4 		$374K Buy
+90,236
New +$285K ﹤0.01% 735
2017
Q3 		– Sell
-20,000
Closed -$210K – 1827
2017
Q2 		$210K Buy
+20,000
New +$261K ﹤0.01% 1539

Other funds holding OVID

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Laurion Capital Management's OVID Position: Q1 2020 in Review

Laurion Capital Management sold out of Ovid Therapeutics (OVID) in Q1 2020, closing a stake of 90,236 shares — an estimated $374K sold.

Laurion Capital Management first reported a position in OVID in Q2 2017 and held it in 2 quarters. The position peaked at $374K in Q4 2019. 57 funds tracked by Wall St. Rank hold OVID as of Q1 2020.

  • Laurion Capital Management reported no remaining Ovid Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Laurion Capital Management sold 90,236 Ovid Therapeutics shares in Q1 2020, an estimated $374K.
  • Laurion Capital Management first reported a position in Ovid Therapeutics in Q2 2017 and held it in 2 quarters.
  • Laurion Capital Management's Ovid Therapeutics position peaked at $374K in Q4 2019.
  • 57 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2020.

Based on Laurion Capital Management's 13F filing for Q1 2020, filed 14 May 2020.